Mizuho raises Boston Scientific target to $130, maintains Outperform
Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while maintaining an Outperform rating. The revision follows a series of positive developments reported by the medical device company,
Boston Scientific price target raised to $122 from $119 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating
Boston Scientific (NYSE:BSX) Price Target Raised to $115.00
Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.
Boston Scientific sees higher-than-expected 2025 profit on strong demand
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Boston Scientific price target raised to $120 from $110 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $120 from $110 and keeps a Buy rating on the
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO Kenneth Stein - Chief Medical Officer
Truist lifts Boston Scientific stock target to $120, maintains Buy
Truist Securities expressed a positive outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $120 from $110, while reaffirming a Buy rating. The stock, currently trading near its 52-week high of $107.
Truist Financial Sticks to Their Buy Rating for Boston Scientific (BSX)
Truist Financial analyst Richard Newitter maintained a Buy rating on Boston Scientific (BSX – Research Report) today and set a price target of
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank,
Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
Boston Scientific Corporation (NYSE:BSX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...
MassDevice1d
Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
BioWorld19h
Boston Sci’s Farapulse tops $1B in 2024, bright prospects for 2025
As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...
5BSX : Boston Scientific Clocks 22% Jump In Q4 Sales On Strong...
Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.
Boston Scientific remains bullish despite tariffs with sales buoyed by Minnesota tech
Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...
Hosted on MSN20h
How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat
Boston Scientific stock jumped Wednesday after the medtech giant easily beat Wall Street's fourth-quarter expectations and its own guidance.